Over the past decade, neuroeconomics studies utilizing neurophysiology methods (fMRI or EEG) have flourished, revealing the neural basis of 'boundedly rational' or 'irrational' decision-making that violates normative theory. The next question is how modulatory neurotransmission is involved in these central processes. Here I focused on recent efforts to understand how central monoamine transmission is related to nonlinear probability weighting and loss aversion, central features of prospect theory, which is a leading alternative to normative theory for decision-making under risk. Circumstantial evidence suggests that dopamine tone might be related to distortion of subjective reward probability and noradrenaline and serotonin tone might influence aversive emotional reaction to potential loss.
Introduction
Should I take an umbrella with me this morning? Should I buy life insurance? To answer these questions, and choose, we need to estimate the probability of the possible outcomes and magnitudes of possible gain and loss. For instance, we need to take into account the possible damage due to a severe health problem, the insurance premium, and the probability of being involved in a serious health problem.
Normative theory in decision-making under risks assumes that people combine probabilities and valuation (utility) of possible outcomes in some way, most typically by taking the probability-weighted expectation over possible utilities. While this expected utility theory is the dominant model, experimental and field studies have repeatedly shown that decision-makers systematically violate it [1] . Over the past decade, a synthesis of economics and neuroscience called neuroeconomics utilizing neurophysiology methods (fMRI or EEG) has flourished, revealing the neural basis of 'boundedly rational' or 'irrational' decision-making that violates normative theory. Past neuroeconomics studies have demonstrated that, in addition to cortical regions such as the prefrontal cortex (PFC), subcortical emotion-related brain structures play a major role in 'irrational' decisionmaking [2] . The next question is how modulatory neurotransmission is involved in these central processes [3, 4] . Here, I provide an overview of recent efforts to understand the neurochemical basis of 'irrational' decision-making under risks especially with regard to prospect theory.
Nonlinear probability weighting
One type of systematic departure from normative economic theory is that subjective weights on probabilities appear to be nonlinear. Decision-makers often overestimate low probabilities (e.g. playing lotteries) and underestimate high probabilities. A leading alternative to the expected utility theory is the prospect theory [5] , a central feature of which is nonlinear probability weighting. Objective probabilities, p, are transformed nonlinearly into decision weights w( p) by a weighting function (Figure 1a ). Experimental studies suggest that the weighting function is regressive, asymmetric, and inverse S-shaped, crossing the diagonal from above at an inflection point (around 1/3) where p = w( p). Although several functions have been proposed to express nonlinear probability weighting, the one-parameter function derived axiomatically by Prelec [6] , w( p) = exp{À(ln(1/ p)) a } with 0 a 1, is widely used because it typically fits as well as other functions with one or two parameters [7] . And because nonlinearity is fully captured by a single parameter, it is simple to correlate the degree of nonlinearity (a) across individuals with biological measures such as receptor density. This w( p) function has an inverted-S shape with a fixed inflection point at p = 1/ e = 0.37 (at this point the probability 1/e also receives decision weight 1/e). In an inverse S-shaped nonlinear weighting function, low probabilities are overweighted and moderate to high probabilities are underweighted. The function neatly explains the typically observed pattern of risk-seeking for low probability gain and risk aversion toward high probability gain.
Paulus and Frank [8] investigated the neural substrates that are related to nonlinear probability transformation using fMRI with a certainty equivalent procedure. During this procedure, a gamble's certainty equivalent, the amount of sure payoff at which a player is indifferent between the sure payoff and the gamble, was determined. The authors found that differential anterior cingulate activation during estimation of high probabilities relative to low probabilities was positively correlated with Prelec's nonlinearity parameter a across subjects. Another fMRI study with risks of electric shocks found similar nonlinear response in brain regions including the caudate/subgenual anterior cingulate [9] . Tobler et al. [10] reported that the dorsolateral PFC was involved in overweighting low probabilities and underweighting high probabilities, and that the ventral frontal regions showed the opposite pattern. More recently, Hsu et al. [7] reported that the degree of nonlinearity in the neural response to anticipated reward in the striatum reflected the nonlinearity parameter as estimated behaviorally. The discrepancies regarding the loci of activation are thought to stem from differences in the task (probability range, context, etc.) and analysis of parameter estimation. However, it is reasonable to investigate the relationship between the dopamine (DA) system and nonlinear probability weighting, considering the fact that DA is linked to risk-seeking behavior [11] and excessive DA release was observed in pathological gambling in Parkinson's disease patients [12] . Trepel et al. [4] hypothesized in a thoughtful review that DA transmission in the striatum might be involved in shaping probability weighting. In order to test this speculation, we utilized in vivo molecular neuroimaging by positron emission tomography (PET) to examine central DA transmission and nonlinear probability weighting.
Certainty equivalents were determined outside the PET scanner, and we estimated probability weighting using the Prelec's one-parameter function [6] .
The finding was that striatal D1 receptor binding measured by [ [13 ] . That is, people with lower striatal D1 receptor binding tend to show more pronounced overestimation of low probabilities and underestimation of high probabilities. [ 11 C]SCH23390 is a selective radioligand for D1 receptors, but it also has some affinity for serotonin (5-HT) 2A receptors. 5HT2A receptor density in the striatum is negligible compared to D1 receptor density. However, 5HT2A receptor density is never negligible in extrastriatal regions, and a recent in vivo study reported that approximately one-fourth of the cortical signal of [ 11 C]SCH23390 was due to binding to 5HT2A receptors [14] . The role of extrastriatal D1 receptors in nonlinear weighting needs to be tested with a more selective radioligand in future studies.
Although nonlinear probability weighting is a combination of risk-seeking (overestimation of low probability) and risk-aversion (underestimation of high probability), in a clinical setting, the excessive overestimation of low probability of winning a gamble might be more problematic. Clinical studies have reported the emergence of pathological gambling in Parkinson's disease patients taking DA agonist medication [15, 16] , and such patients demonstrated enhanced DA release in the ventral striatum measured by [ 11 C]raclopride PET during gambling [12] . Although pathological gambling is a complex behavior and cannot be solely attributed to mis-estimating probability, these observations can lead to the conjecture that excessive DA transmission might cause distortion of subjective reward probability (Figure 1a) . From a psychological point of view, the overweighting of low-probability gains may reflect the hope of winning, and it is straightforward to link DA tone and overweighting of low probability. Underweighting of high-probability gains may reflect the fear of losing a 'near sure thing'. In addition to DA [17, 18] , 5-HT [17] and NE [19] are also known to modulate the emotional reaction of fear, and the shape of weighting function in the high-probability portion should be determined by multiple neurotransmitters other than DA.
Loss aversion
Pain derived from losing a certain amount of money appears to be greater than the pleasure derived from gaining the same amount. Imagine having a chance to participate in a coin flip game of chance. Using a fair coin, if the result is heads, you will win $100, and if the result is tails, you will lose $100. Are you willing to participate in this gamble? Typically, most people would say 'no'. Well, how about the following gamble? If the result is heads, you will win $200, and if the result is tails, you will lose $100. In this case, some people would say 'yes'. This means that, typically, losses have at least twice the impact of equivalent gains, a property called loss aversion [20] . Many laboratory and field studies have found evidence in monkeys for food rewards, and in humans for financial outcomes, features of consumer goods, food rewards, game show winnings, and apartment sales [1, 21, 22] . In prospect theory, this is modeled by a value function of losses that is steeper than that of gains (Figure 1b) . A recent fMRI study has shown that the PFC and striatum are involved in loss aversion [23] . Brain lesion studies have reported that amygdala lesion patients showed diminished loss aversion [24 ] . Sokol-Hessner et al. [25 ] described that physiological arousal response (skin conductance response) to losses was greater than to equivalent gains on average. This means that losses are more emotionally laden and salient than equivalent gains. The study also reported that individuals with greater arousal response to losses versus gains tend to be more loss-aversive. More recently, the same authors, using fMRI, revealed that behavioral loss aversion was correlated with amygdala activity in response to losses relative to gains [26] .
It is widely acknowledged that 5-HT plays a major role in emotional response or affective state. Although there are no PET studies on the relationship between 5-HT transmission and loss aversion, circumstantial evidence suggests that central 5-HT tone might be associated with loss aversion. Enhancing 5-HT transmission by tryptophan supplement reduced the 'reflection effect' [27 ] . 'Reflection effect' refers to the fact that decision-makers Positive correlation between striatal D1 receptor binding and a of the weighting function is shown. Panels were taken and modified from [13] .
tend to prefer the guaranteed $50 gain to a 50/50 gamble to win $100 or no gain at all, showing risk-aversion. However, decision-makers tend to prefer a 50/50 gamble to lose $100 or no loss at all to the guaranteed $50 loss, showing riskseeking. 'Reflection effect' and 'framing effect' can be partially explained using loss aversion. De Martino et al. [28] reported that susceptibility to the framing effect was associated with amygdala activation. Then they reported that genetic variation in the promoter region of the 5-HT transporter gene (5-HTTTLPR) predicted the susceptibility to the framing effect. Homozygosity for s allele showed greater amygdala activation during decision-making and stronger framing effect than l carriers [29 ] . More recently, large-sample behavioral economics studies in a Chinese sample also showed that homozygosity for s allele showed higher loss aversion than l carriers [30] . It is difficult to estimate pre-and post-synaptic (and net) 5-HT transmission by genetic variation in 5-HTTTLPR [31] , but 5-HT neurotransmission seems to ease the aversion to financial loss (Figure 1b) .
In addition to 5-HT, a line of evidence suggests that norepinephrine (NE) might be involved in loss aversion. The role of NE in arousal is well established [32] , and physiological arousal response was reported to be associated with behavioral loss aversion [25 ] . Central NE blockade by propranolol attenuated the sensitivity to the magnitude of possible losses at gambles [33] . Lack of appropriate PET radioligand has prevented us from investigating the role of central NE transmission in cognition, emotion and decision-making in vivo. However, (S,S)-18F-FMeNER-D2 has recently been developed as a radioligand for the measurement of norepinephrine transporter for PET [34, 35] . (S,S)-18F-FMeNER-D2 is a reboxetine analog and has high affinity and high selectivity for norepinephrine transporter. We utilized positron emission tomography (PET) scans with (S,S)-[ 18 F]FMeNER-D 2 to investigate the relationship between central NET and loss aversion [36 ] . A NET-rich region available to PET imaging with this ligand is the thalamus. The amygdala and PFC are also innervated by NE, but the relatively low expression of NET prevented reliable measurement of their NET binding.
Loss aversion parameters were determined outside the PET scanner using a 50:50 mixed gamble (gain-loss). This parameter l is similar to the parameter in prospect theory but makes the common simplifying assumptions of a linear rather than curvilinear value function (Figure 1b) , and identical decision weights for a 0.5 probability of a gain or loss. The finding was that there was a negative correlation between l and NET binding in the thalamus (Figure 3 ). That is, individuals with low thalamic NET tend to show pronounced loss aversion. Although NE has been implicated in arousal, recent studies also suggest that NE affects processing of salient information [32] . Neurons of the locus coeruleus (LC), the major source of NE in the brain, are phasically evoked by salient or emotional stimuli [37] , and phasic LC activation also increases NE release in target sites [32] . Increasing NE tone by NE reuptake inhibitor improves detection of emotional stimuli [38] , and blockade of central NE by propranolol predominantly impairs processing of negatively emotional stimuli [39] . Thus, PET findings suggest that individuals with low NET in the thalamus might show enhanced effect of NE released by salient stimuli due to low re-uptake, and consequently show pronounced emotional or arousal response to losses relative to gains. Thalamic NET might be an indirect mediator of the relationship between NE transmission and loss aversion. Similarly to 5-HT systems, Monoamines and assessment of risks Takahashi 1065 Rasch et al. [40] reported that a genetic variation of ADRA2B, the gene encoding the a2b-adrenergic receptor, predicted the amygdala responsivity to negative emotional stimuli. Future studies with a more appropriate radioligand for measuring NET in the amygdala and PFC, which are innervated by NE and implicated in loss aversion, are recommended. For the present, it is not unreasonable to suppose that central NE tone contributes to shaping the slope of the value function in the loss domain (Figure 1) .
Recently, Preuschoff et al. [41] investigated the relationship between pupil dilation and surprise associated with decision outcome. Surprise was defined as the difference between predicted outcome and actual outcome. Although skin conductance response or pupil dilation is a peripheral response, several lines of evidence support the concept of a link between these peripheral responses and the central NE level [42] . Compared to the DA system, the role of the NE system in reward processing has been less studied, and specifically, the research field that would elucidate the role of NE in 'emotional' or 'irrational' decision-making under risk is worthy of further development.
Conclusion
The PET technique is a powerful tool for investigating the relationship between neurotransmitters and decisionmaking in vivo in human. However, standard PET studies tell us only the correlational relationship. Complementary pharmacological studies as well as animal studies are needed for a full understanding of the causal relationship. Mis-estimating risk could lead to disadvantaged choices such as initiation of drug use/gambling and transition to regular drug use/gambling [43 ] . An interdisciplinary approach combing molecular imaging techniques and cognitive neuroscience and clinical psychiatry will provide new perspectives for understanding the neurobiology of impaired decision-making in neuropsychiatric disorders and their drug development [44] .
